About Us

Annual
Conference

News &
Blog

Jobs

All Publications Webinars Blogs
Maps
Staff
Jobs
Toolkits
Charts

Menu   ≡
╳

Home

Resources

TOPIC

Behavioral
Health

Care
Coordination

Children’s
Health

Delivery
System Reform

Eligibility
and Enrollment

Health IT

Insurance
Exchanges

Long Term and
Chronic Care

.

Medicaid

Oral Health

Payment
Reform

Pharmaceutical Costs

Population
& Public Health

Primary Care
and Medical Homes

State
Refor(u)m

Quality and
Performance Measurement

CONTENT TYPE

Publications

Webinars

Blogs

Charts

Maps

Toolkits

State Exchanges

Drug Pricing

Event

Webinars

Annual Conference

Supreme
Court Decision Removes Barrier to Importing US Patented Drug Products at Lower
Cost

This blog
looks at how a recent Supreme Court decision on printer cartridges could help
pave the way for wholesale drug importation. In Impression Products, Inc. v
Lexmark International Inc., the Supreme Court ruled patent law cannot be used
to prevent the resale of products back into the United States. The case is an
important ruling in the context of the domestic policy debate concerning
prescription drug pricing. Importation of prescription drugs as an antidote to
the high prices in the U.S. is popular with the public and many policymakers.
Read
more.

State
Wholesale Importation Program Explained

There is growing public pressure to find an effective
way to address the rising prices of prescription drugs. Among the variety of
approaches aimed at managing drug prices, importation from other countries is
one that comes up repeatedly. The NASHP Pharmacy Costs Work Group believes
there is a way for the federal government and states to get to ‘yes’ on a
program of wholesale importation. The diverse group of state officials who
comprise this Work Group have developed a wholesale drug importation program
that would meet the major federal law criteria that the HHS Secretary must
certify in order for a program to move forward. Read
the full publication.

Request
for Proposals: State Drug Spending and Pricing Policy Initiatives

As part of the launch of the Center for State Rx Drug
Pricing, NASHP is requesting proposals from states for initiatives to develop
and implement innovative approaches to contain the costs of prescription
drugs. This is a multi-year project to assist state executive, legislative,
and independent agencies and offices with prescription drug pricing
policies.

Update:
What’s New in State Drug Pricing Legislation?

With 80 bills introduced in 2017, there is a high level
of interest in pharmaceutical pricing among state legislators. However,
despite legislative sessions wrapping up, very few laws have been enacted. The
latest NASHP blog
examines the bills passed so far, in Maryland, Montana, New Mexico, New York,
and Utah. Read
the full blogpost here.

Home

Center for State Rx Drug
Pricing

Center for State Rx Drug Pricing

The Laura and John Arnold Foundation and Kaiser Permanente funded the NASHP
Pharmacy Price Work Group during 2016 that delivered a set of new state-based
policy approaches, and refined and reshaped other previously proposed policies
intended to constrain pharmaceutical pricing. The set of policy approaches
described in “States
and the Rising Costs of Pharmaceuticals: A Call to Action” has been well
received by states and stakeholders.

Our task now is to facilitate the next phase of work among states wanting to
move forward with these different policies. We also need to build an analytic
foundation for some of the more complex, but potentially more rewarding, policy
approaches that are not yet ready for implementation.
Read More

To move the state agenda forward, the Laura and John Arnold Foundation has
funded NASHP to establish the NASHP Center for State Drug Price Action. The
Center is staffed by Jane Horvath, who brings expertise from work both in the
pharmaceutical industry and the federal government, who will direct the
initiative, help  promote it with states and support state-based
implementation. In brief, the Center will provide technical and strategic
assistance to states, leverage legal and actuarial expertise for states as
needed, distribute funding to a subset of states, and convene the Work Group to
address policy and strategic issues that arise during this next phase of the
project. The Center will also engage other state organizations to advance the
states’ drug price policy agenda, and, lastly, disseminate learnings – successes
and challenges – among states.

NASHP’s Pharmacy Costs Work Group is
comprised of state leaders from governors’ staff, state legislatures, Medicaid
programs, public employees, attorney generals’ offices, state-based insurance
exchanges, comptrollers’ offices, and corrections departments. The group aimed
to find new approaches to limit pharmaceutical costs by examining the many
levers state governments have as policymakers, regulators, and purchasers.

Susan Barrett, J.D., Executive Director, Green
Mountain Care Board

Burl Beasley, D.Ph., MPH, MS Pharm Clinical
Pharmacist, Oklahoma Health Care Authority

Robert Crittenden, M.D., Senior Policy Advisor to
Governor, Washington

James DeBenedetti Director, Plan
Management Division, Covered California

Rebekah Gee, Secretary, Dept. of
Health and Hospitals, State of Louisiana

Rory Griffin, Deputy Director, Arkansas Dept.
of Corrections

Richard Gottfried, Chair,
Committee on Health, New York Assembly

Emily Hancock, RPH, Phar. D.,
MPA Clinical Pharmacist, Indiana Dept. of Social and Family
Services

Nathan Johnson, Chief Policy
Officer, Washington State Health Care Authority

Heather Korbulic, Executive
Director, Silver State Health Insurance Exchange

Kevin Lembo, Comptroller, State of
Connecticut

Janet Mills, J.D., Attorney
General, State of Maine

Rebecca Pasternik-Ikard, Chief
Executive Officer, Oklahoma Health Care Authority

Sara Sadownik, Deputy Chief of Staff,
Massachusetts Health Policy Commission

David Seltz, Executive Director,
Massachusetts Health Care Commission

Norman Thurston, Ph.D., Utah State
Legislature

Eileen Mallow, Deputy Director, WI
Dept. of Employee Trust Funds

Linda Wiant, Chief, Medical Assistance Plans,
State of Georgia

Josh Wojcik, Policy Director, Connecticut
Office of the Comptroller

Trish Riley, Chair, Executive Director,
NASHP

Please find information for all upcoming webinars of the Pharmacy Cost Work
Group here, as well as the recordings and slide decks of previous webinars:

• States
and the Rising Costs of Pharmaceuticals: A Call to Action, January 11th,
2017

State policy makers interested in model legislation produced by this
workgroup may request access to a legislators guide and additional background
materials. Please contact Corinne
Alberts if you wish to receive this state-only material.

For more information, please contact Jane
Horvath, staff lead for this project.

This Resource Center was made possible with support from Laura and John
Arnold Foundation and produced by NASHP Pharmacy Costs Work
Group.

Featured Products

Pharmacy
Costs Work Group – Model Legislation

States and the Rising Cost of Pharmaceuticals: A Call to
Action

State Legislative Action on Pharmaceutical Prices

Latest Resources

Request for Proposals: State Drug Spending and Pricing Policy
Initiatives

The National Academy for State Health Policy (NASHP), with support from the
Laura and John Arnold Foundation, today launched the Center for State Rx Drug
Pricing. Building on the work of the Pharmacy Costs Work Group, the Center
will provide technical and strategic assistance to states, leverage legal and
actuarial expertise as needed, distribute funding […]

June 20, 2017 | Filed under: Front Page-Rx, Pharmaceutical Costs, Prescription Drugs

Supreme Court Decision Removes Barrier to Importing US Patented
Drug Products at Lower Cost

In its May 30, 2017 decision Impression Products, Inc. v Lexmark
International Inc., the Supreme Court ruled that patent law cannot be used to
prevent the resale of products back into the United States. The Court case
specifically concerned printer toner cartridges, but it is an important ruling
in the context of the domestic policy […]

June 6, 2017 | Filed under: Blog Posts, Drug Pricing, Front Page, Front Page-Rx, Pharmaceutical Costs, State Health Policy Blog

State Wholesale Importation Program Explained

Because the federal government has not been able to agree on an approach to
constrain prescription drug prices, states need to address the problem. Study
after study show how U.S. consumers pay the highest prices in the world for
life-saving and life-enhancing drug treatments. The prices we pay may fund the
research and development that […]

May 30, 2017 | Filed under: Drug Pricing, Front Page, Front Page-Rx, Pharmaceutical Costs, Prescription Drugs, Publications

Managing High Drug Prices through Importation: We Can Get to
“YES”

There is growing public pressure to find an effective way to address the
rising prices of prescription drugs. Multiple drug price bills await action in
Congress and more than 80 bills have been introduced in state legislatures in
2017. Among the variety of approaches aimed at managing drug prices,
importation from other countries is an […]

May 30, 2017 | Filed under: Drug Pricing, Front Page, Front Page-Rx, Pharmaceutical Costs, Prescription Drugs, State Health Policy Blog

Update: What’s New in State Drug Pricing Legislation?

With 80 bills introduced in 2017, there is a high level of interest in
pharmaceutical pricing among state legislators. However, despite legislative
sessions wrapping up, very few laws have been enacted. To date, bills have
passed in Maryland, Montana, New Mexico, New York, and Utah. In 2016, Vermont
led the way with a price transparency […]

May 1, 2017 | Filed under: Blog Posts, Drug Pricing, Front Page, Front Page-Rx, Maryland, Montana, New Mexico, New York, Pharmaceutical Costs, State Health Policy Blog, Utah

For a full list of our Pharmaceutical Costs resources, click the Rx Center's
logo below!

Site Map

Privacy
Policy

Terms of
Use

Contact Us

Phone:202-903-0101

Portland, Maine Office:

10 Free St., Second Floor
Portland, Maine 04101
P: 207-874-6524
F:
207-874-6527

Washington, DC Office:

1233 20th St., N.W., Suite 303
Washington, DC 20036
P: 202-903-0101

F: 202-903-2790

Copyright © 2015, by The National Academy for State
Health Policy. All rights reserved. May not be published or otherwise
distributed without explicit permission.